HUTCHMED (China) Limited (FRA:H7T2)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.24B -0.6% |
| Revenue (ttm) | 480.65M -8.8% |
| Net Income | 15.65M -96.2% |
| EPS | 0.02 -96.2% |
| Shares Out | n/a |
| PE Ratio | 133.22 |
| Forward PE | 39.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 2.420 |
| Previous Close | 2.380 |
| Day's Range | 2.420 - 2.420 |
| 52-Week Range | 1.650 - 2.860 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About HUTCHMED (China)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet... [Read more]
Financial Performance
In 2025, HUTCHMED (China)'s revenue was $548.51 million, a decrease of -12.96% compared to the previous year's $630.20 million. Earnings were $456.91 million, an increase of 1111.03%.
Financial numbers in USD Financial StatementsNews
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO ® —
Is HUTCHMED (China) Ltd (HCM) Overvalued After 4.0% Rally? GF Value Says Overvalued
Is HUTCHMED (China) Ltd (HCM) Overvalued After 4.0% Rally? GF Value Says Overvalued
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its annou...
HUTCHMED (China) Ltd (HCM) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 78/100
HUTCHMED (China) Ltd (HCM) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 78/100
HUTCHMED (China) Ltd (HCM) Shares Fall 4.3% -- What GF Score of 77 Tells Investors
HUTCHMED (China) Ltd (HCM) Shares Fall 4.3% -- What GF Score of 77 Tells Investors
HUTCHMED (China) Ltd (HCM) Shares Surge 3.4% -- What GF Score of 79 Tells Investors
HUTCHMED (China) Ltd (HCM) Shares Surge 3.4% -- What GF Score of 79 Tells Investors
HUTCHMED Seeks FDA Approval For ORPATHYS-TAGRISSO In Resistant Lung Cancer
(RTTNews) - HUTCHMED (HCM) announced that AstraZeneca (AZN) has submitted a New Drug Application to the U.S. FDA for ORPATHYS in combination with TAGRISSO for certain patients with advanced non-small ...
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
HUTCHMED (China) said on Tuesday Anglo-Swedish drugmaker AstraZeneca had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in pat...
Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC
Hutchmed (HCM) “announces that AstraZeneca (AZN) has submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS (savolitinib) plus TAGRISSO(R) (osimertinib) for the treatment...
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —
Hutchmed (HCM) Launches Phase Ia Trial for HMPL-A830 in Advanced Solid Tumors
Hutchmed (HCM) Launches Phase Ia Trial for HMPL-A830 in Advanced Solid Tumors
HUTCHMED Starts Global Phase 1 Trial Of KRAS-EGFR Therapy HMPL-A830 In Solid Tumors
(RTTNews) - HUTCHMED (China) Limited (HCM) on Monday announced the initiation of the Phase 1a portion of a global clinical trial evaluating HMPL-A830 in patients with unresectable, advanced or metasta...
Hutchmed initiates Phase Ia part of trial of HMPL-A830
Hutchmed (HCM) announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors. The first patient…
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated...
HUTCHMED (China) Ltd (HCM) Shares Fall 3.3% -- What GF Score of 79 Tells Investors
HUTCHMED (China) Ltd (HCM) Shares Fall 3.3% -- What GF Score of 79 Tells Investors
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from sever...
Hutchmed price target raised to $18 from $16 at BofA
BofA raised the firm’s price target on Hutchmed (HCM) to $18 from $16 and keeps a Buy rating on the shares. Despite falling off all-time highs over the past month,…
HUTCHMED (China) Ltd (HCM) Stock Down 3.2% -- Now Undervalued? GF Score: 81/100
HUTCHMED (China) Ltd (HCM) Stock Down 3.2% -- Now Undervalued? GF Score: 81/100
Hutchmed upgraded to Buy from Hold at HSBC
HSBC upgraded Hutchmed (HCM) to Buy from Hold with a HK$17.40 price target
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The t...
Hutchmed upgraded to Buy from Hold at Daiwa
Daiwa analyst Jing Yang upgraded Hutchmed (HCM) to Buy from Hold with an $18.50 price target The firm views the company’s commercialization agreement with GSK as a “major positive surprise.”…
HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal
HUTCHMED stock soared on Thursday after the company announced a new licensing deal with GlaxoSmithKline.
HUTCHMED (China) Transcript: Status update
A major licensing and co-development deal with GSK for HMPL-A830 accelerates global development and validates the ATTC platform, with HUTCHMED leading phase I trials and GSK taking ex-China rights. The agreement includes $1.3 billion in potential value and tiered royalties.
HUTCHMED (China) Press release: Status update
HUTCHMED (China) issued a press release on September 3, 2026, disclosing material business information to investors.